Redefining second-line strategy after MonumenTAL-3, MajesTEC-3, and MajesTEC-9 (presented at the EHA 2026 Congress).

Authors

Peter M Voorhees

Published in

Clinical advances in hematology & oncology : H&O. Volume 24. Issue 6 Suppl 8. Pages 4-7.

PMID:
42748348
Bibliographic data and abstract were imported from PubMed on 17 Sep 2026.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.